Skip to main content
. Author manuscript; available in PMC: 2021 Jul 15.
Published in final edited form as: Cancer Res. 2020 Oct 21;81(2):248–253. doi: 10.1158/0008-5472.CAN-20-2959

Figure 1:

Figure 1:

Mechanism of MYCi efficacy. MYCi directly binds to MYC, induces phosphorylation of threonine 58 leading to MYC degradation. MYCi inhibits MYC/MAX heterodimerization, blocking MYC-dependent transcription and proliferation. Following MYCi treatment, the tumor microenvironment is altered by infiltration of diverse immune effector cells and increased PD-L1 expression. Combination of MYCi with anti-PD-1/PD-L1 therapy results in improved efficacy.